Your browser doesn't support javascript.
loading
ANKRD49 promotes the invasion and metastasis of lung adenocarcinoma via a P38/ATF-2 signalling pathway.
Liu, Yue-Hua; Yuan, Meng; Xu, Bai-Xue; Gao, Rui; You, Yu-Jie; Wang, Zhi-Xin; Zhang, Yong-Cai; Guo, Min; Chen, Zhao-Yang; Yu, Bao-Feng; Wang, Qi-Wei; Wang, Hai-Long; Pang, Min.
Afiliación
  • Liu YH; School of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
  • Yuan M; Xi'an Jiaotong University-Affiliated Honghui Hospital, Xi'an, China.
  • Xu BX; School of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
  • Gao R; School of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
  • You YJ; Department of Pulmonary and Critical Care Medicine, The First Hospital, Shanxi Medical University; Shanxi Province Key Laboratory of Respiratory Disease, Taiyuan, China.
  • Wang ZX; School of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
  • Zhang YC; School of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
  • Guo M; Department of Cardiothoracic Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China.
  • Chen ZY; Laboratory of Animal Center, Shanxi Key Laboratory of Experimental Animal Science and Animal Model of Human Disease, Shanxi Medical University, Taiyuan, China.
  • Yu BF; Laboratory of Animal Center, Shanxi Key Laboratory of Experimental Animal Science and Animal Model of Human Disease, Shanxi Medical University, Taiyuan, China.
  • Wang QW; School of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
  • Wang HL; Class ZT011907, The First Clinical Medical College, Shanxi Medical University, Jinzhong, China.
  • Pang M; School of Basic Medicine, Basic Medical Science Center, Shanxi Medical University, Jinzhong, China.
J Cell Mol Med ; 26(16): 4401-4415, 2022 08.
Article en En | MEDLINE | ID: mdl-35775112
ABSTRACT
Lung adenocarcinoma (LUAD) is the most challenging neoplasm to treat in clinical practice. Ankyrin repeat domain 49 protein (ANKRD49) is highly expressed in several carcinomas; however, its pattern of expression and role in LUAD are not known. Tissue microarrays, immunohistochemistry, χ2 test, Spearman correlation analysis, Kaplan-Meier, log-rank test, and Cox's proportional hazard model were used to analyse the clinical cases. The effect of ANKRD49 on the LUAD was investigated using CCK-8, clonal formation, would healing, transwell assays, and nude mice experiment. Expressions of ANKRD49 and its associated downstream protein molecules were verified by real-time PCR, Western blot, immunohistochemistry, and/or immunofluorescence analyses. ANKRD49 expression was highly elevated in LUAD. The survival rate and Cox's modelling analysis indicated that there may be an independent prognostic indicator for LUAD patients. We also found that ANKRD49 promoted the invasion and migration in both in in vitro and in vivo assays, through upregulating matrix metalloproteinase (MMP)-2 and MMP-9 activities via the P38/ATF-2 signalling pathway Our findings suggest that ANKRD49 is a latent biomarker for evaluating LUAD prognosis and promotes the metastasis of A549 cells via upregulation of MMP-2 and MMP-9 in a P38/ATF-2 pathway-dependent manner.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma del Pulmón / Neoplasias Pulmonares / Proteínas Musculares Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: J Cell Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenocarcinoma del Pulmón / Neoplasias Pulmonares / Proteínas Musculares Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: J Cell Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2022 Tipo del documento: Article País de afiliación: China
...